In conclusion, this study uncovers the neuroprotective mechanism of the CCNE1‐PARP16 regulatory axis in PD through a multidimensional evidence chain, offering potential biomarkers for the early diagnosis of PD, such as CCNE1 expression levels and PARP16 activity. This evidence concerns the gene PARP16 and Parkinson disease.